FODIPIR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H32N4O14P2
Molecular Weight	638.4554
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC=C(COP(O)(O)=O)C(CN(CCN(CC(O)=O)CC2=C(O)C(C)=NC=C2COP(O)(O)=O)CC(O)=O)=C1O

InChI

InChIKey=SQKUFYLUXROIFM-UHFFFAOYSA-N

InChI=1S/C22H32N4O14P2/c1-13-21(31)17(15(5-23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-18-16(12-40-42(36,37)38)6-24-14(2)22(18)32/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38)

HIDE SMILES / InChI

Molecular Formula	C22H32N4O14P2
Molecular Weight	638.4554
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

PubMed

Title	Date	PubMed
Volumetric MR imaging of the liver and applications.	2001 Nov	11694434
Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.	2001 Oct-Dec	11754328
Contrast-enhanced magnetic resonance cholangiography using mangafodipir compared with standard T2W MRC sequences: a pictorial essay.	2004 Aug	15269951
Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.	2004 Oct	15390224
Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.	2004 Sep	15343134
Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.	2005 Mar-Apr	15772534
Ultrasound of living donor liver transplantation.	2006 Apr	21614227
Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.	2006 Feb 15	16478742
The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity.	2006 Jan 1	16397277
MR contrast agents for liver imaging: what, when, how.	2006 Nov-Dec	17102040
Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.	2006 Sep	16941248
Value of manganese-enhanced T1- and T2-weighted MR cholangiography for differentiating cystic parenchymal lesions from cystic abnormalities which communicate with bile ducts.	2007 Dec 31	18159606
[Contrast-enhanced magnetic resonance cholangiography using gadolinium-EOB-DTPA. Preliminary experience and clinical applications].	2007 Jun	17965849
Mangafodipir as a cytoprotective adjunct to chemotherapy--a case report.	2009	19169914
Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.	2009 Oct	19834427
Prevention of 7β-hydroxycholesterol-induced cell death by mangafodipir is mediated through lysosomal and mitochondrial pathways.	2010 Aug 25	20452343

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:28:42 GMT 2023` Edited by `admin` on `Fri Dec 15 15:28:42 GMT 2023`
Record UNII	P28BIW0UTB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FODIPIR

Official Name

English

FODIPIR [USAN]

Common Name

English

DPDP

Code

English

fodipir [INN]

Common Name

English

GLYCINE, N,N'-1,2-ETHANEDIYLBIS(N-((3-HYDROXY-2-METHYL-5-((PHOSPHONOOXY)METHYL)-4-PYRIDINYL)METHYL)-

Systematic Name

English

N,N'-1,2-ETHANEDIYLBIS(N-((3-HYDROXY-2-METHYL-5-((PHOSPHONOOXY)METHYL)-4-PYRIDINYL)METHYL)GLYCINE)

Systematic Name

English

Code System Code Type Description

EVMPD

SUB07772MIG